Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis

Cancer

Volumn 83, Issue 5, 1998, Pages 1002-1011

  Heidenreich, Axel ^a,c   Sesterhenn, Isabell A ^b   Mostofi, F Kash ^b   Moul, Judd W ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Embryonal carcinoma; Nonseminomatous germ cell tumor; Prognostic risk factors; Testicular cancer; Vascular invasion

Indexed keywords

CATHEPSIN D; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER INVASION; CANCER STAGING; EMBRYONAL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TESTIS CARCINOMA;

ANTIGENS, NUCLEAR; CADHERINS; CATHEPSIN D; GERMINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODE EXCISION; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROPERITONEAL NEOPLASMS; RISK FACTORS; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032169646     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A     Document Type: Article

References (36)

1. Donohue JP, Thornhill RS, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Br J Urol 1993;71:326-31.
2. Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 1996;155:1296-8.
3. Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 1982;2:678-80.
4. Moul JW, Heidenreich A. Prognostic factors in low stage nonseminomatous testicular cancer. Oncology 1996;10: 1359-74.
5. Fujime M, Chang H, Lin CW, Prout GR. Correlation of vascular invasion and metastasis in germ cell tumors of the testis: a preliminary report. J Urol 1984;131:1237-41.
6. Hoskin P, Dilly S, Easton D, Horwich A, Hendry WF, Peckham MJ. Prognostic factors in stage I nonseminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986;7:1031-6.
7. Javadpour N, Young JD. Prognostic factors in nonseminomatous testicular cancer. J Urol 1986;135:497-9.
8. Freedman LS, Jones WG, Peckham MJ, Newlands ES, Parkinsom MC, Oliver RTD, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 1987;2:294-8.
9. Hoeltl W, Kosak D, Pont J, Hawel R, Machacek E, Schempfer M, et al. Testicular cancer: prognostic implications of vascular invasion. J Urol 1987;137:683-5.
10. Dunphy CH, Ayala AG, Swanson D, Ro JY, Logothesis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer 1988;62:1202-6.
11. Fung CY, Kalish LA, Brodksy GL, Richie JP, Garnick MB. Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 1988;6:1467-73.
12. Wishnow KI, Johnson DE, Swanson DA, Tenney DM, Babaian RJ, Dunphy CH, et al. Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 1989;34:339-43.
13. Sesterhenn IA, Weiss RB, Mostofi FK, Stablein DM, Rowland RG, Falkson G, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 1992;10:69-78.
14. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994;54:362-4.
15. Moul JW, Foley JP, Hitchcock CL, McCarthy WF, Sesterhenn IA, Becker RL, et al. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 1993; 150:879-83.
16. Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK, Moul JW. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 1994;152:1133-8.
17. Albers P, Ulbright TM, Albers J, Miller GA, Orazi A, Crabtree W, et al. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. J Urol 1996;155:579-86.
18. Heidenreich A, Schenkmann NS, Sesterhenn IA, Mostofi FK, McCarthy WF, Heidenreich B, et al. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I noseminomatous germ cell tumors. J Urol 1997;158:620-5.
19. Lewis DJ, Sesterhenn IA, McCarthy WF, Moul JW. Immunohistochemical expression of p53 tumor suppressor gene protein in adult testicular germ cell testis tumors: clinical correlation in stage I disease. J Urol 1994;152:418-23.
20. Heidenreich A, Sesterhenn IA, Moul JW. Prognostic risk factors in low stage testicular germ cell tumors. Cancer 1997;79:1641-5.
21. Klepp O, Olsson AM, Henrikson H, Aass N, Dahl O, Stenwig AE, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8:509-18.
22. DeRiese WTW, Orazi A, Foster RS, Donohue JP, Messemer JE. The clinical relevance of p53 expression in early stage nonseminomatous germ cell tumors. J Urol 1993;149:311A.
23. Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP. Mutations of the p53 gene are not detectable in human testicular tumors. Modern Pathol 1994;7:435-9.
24. Strohmeyer T, Fleischhacker M, Imai Y, Slamon DJ, Koeffler HP. Status of the p53 tumor suppressor gene and the MDM2-gene in human testicular tumors. J Urol 1993;149: 311A.
25. Peng HQ, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993;53:3574-8.
26. Schenkman NS, Sesterhenn IA, Washington L, Tong YA, Weghorst C, Buzard GS, et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J Urol 154:617-21.
27. Chresta CM, Masters JRW, Hickman JA. Hypersensitivity of human testicular tumors to etoposide induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 1996;56:1834-41.
28. Tsujimoto Y, Cossmann J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-3.
29. Gerdes J, Lemke H, Baisch H, Wacher HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-2.
30. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scamoini S, et al. PCNA and Ki-67 expression in breast carcinoma: correlation with clinical and biological variables. J Clin Pathol 1992;45:416-21.
31. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RW, Fazio VW. Ki-67 determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: a multivariate analysis. Cancer 1992;70:2602-9.
32. Sadi MV, Barrack ER. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 1991;67:3065-71.
33. Due W, Dieckmann KP, Loy V. Immunohistological determinations of proliferative activity in seminomas. J Clin Pathol 1988;41:304-7.
34. Tandon AK, Clark GM, Chamness GC, Chrigwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
35. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-3.
36. Jiang WG. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg 1996;83:437-46.